- Home
- ETY vs OLMA Comparison
ETY vs OLMA Comparison
Compare ETY & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETY | OLMA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ETY | OLMA |
|---|---|---|
| Price | $14.84 | $24.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 231.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $2.86 |
| 52 Week High | $16.03 | $36.26 |
Technical Indicators
Market Signals| Indicator | ETY | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 46.32 |
| Support Level | $14.89 | $22.97 |
| Resistance Level | $15.71 | $27.38 |
| Average True Range (ATR) | 0.19 | 1.40 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 47.00 | 48.11 |
Price Performance
Historical ComparisonAbout ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.